BASF and Eight Partners Cooperate to Optimize Production Processes for Renewable-Based Products
A consortium of companies in the European process industry from the areas of biotechnology, renewable resources, chemistry, process engineering, equipment supply, as well as research organizations recently launched project PRODIAS (PROcessing Diluted Aqueous Systems). The project focuses on unlocking the potential of renewable-based products made via white biotechnology, by significantly decreasing production costs, increasing productivity and efficiency, lowering energy consumption, and accelerating process developments.
Under the consortial leadership of BASF, the partners include Cargill Haubourdin, France; University of Kaiserslautern, Germany; Imperial College London, UK; Alfa Laval, Sweden; GEA Messo PT, the Netherlands; Xendo, the Netherlands; UPM, Finland; and Enviplan, Germany. These partners will collaborate to develop cost and energy-efficient technologies for water purification, removal and product-recovery needed to support downstream processing in white biotechnology.
Using biotechnological methods such as fermentation or biocatalysis, in most cases the renewable-based products are produced as part of complex dilute aqueous mixtures from which they have to be purified. This includes the removal of a vast amount of water, making the downstream process energy intensive as it often requires many complex consecutive separation steps and thus hampers the cost-competitiveness of products from renewable resources. Furthermore, processing methods developed for chemical production are often used which are insufficiently adapted to biotechnological processes.
PRODIAS aims to address these challenges by developing and implementing cost-effective separation and purification technologies tailored for renewable resources in white biotechnology production processes. Its focus is to adapt separation techniques to the need of white biotechnology products and to design novel hybrid systems combining individual advantages, for example, selectivity and energy efficiency. The bioreactions (fermentations) and biocatalysis by which the valuable products are produced are subject to alteration and optimization, to enable more efficient and resource-saving downstream processing.
The total project budget is about €14 million with the European Union contributing €10 million. EU funding of the PRODIAS project is enabled via the Public-Private Partnership with SPIRE (Sustainable Process Industry through Resource and Energy Efficiency). SPIRE, in turn, is part of Horizon 2020, the EU framework program for research and innovation, which runs from 2014 to 2020 and comprises an €80 billion budget. In partnership with industry, the EU will invest in innovative technologies for sustainable processes.
Related News
-
News Novartis signs US$3.2 bn subcutaneous delivery deal with Alteogen
Swiss pharma giant secures access to Korean biotech's ALT-B4 hyaluronidase platform in milestone-heavy agreement, marking Alteogen's fourth major licensing deal of 2026 as competition intensifies in the subcutaneous drug delivery space.
-
News Women in Pharma: The philosophy of pharmaceutical leadership
In this latest instalment of our Women in Pharma series, we sit down with Clarissa Sowemimo-Coker, Chief Strategy Officer at Ambrose Healthcare and CPHI Middle East Advisory Board Member.
-
News The PSCI Supplier Partnership - Collaboration for Responsible Supply Chains
About the Pharmaceutical Supply Chain Initiative The Pharmaceutical Supply Chain Initiative (PSCI) is the leading, member-led association for pharmaceutical companies working collaboratively to build responsible supply chains. Founded in 2006 and es... -
News AstraZeneca shares plunge 8.9% after reports of BMS talks
Britain's largest drugmaker lost more than GBP£17 billion in market value following reports of preliminary merger discussions with Bristol Myers Squibb that could create a pharmaceutical giant worth nearly US$400 billion, though investors rem... -
News GSK announces £400 million investment in new Cambridge R&D centre
Pharmaceutical giant to establish flagship research facility on Cambridge Biomedical Campus as part of strategic pipeline acceleration
-
News The CPHI Sustainability Summit - Where Conversation Becomes Collaboration
The Report Was Never the Destination - “The future of pharmaceutical sustainability won’t be shaped by individual organisations working in isolation. It will be shaped by partnerships, shared expertise and the willingness to work diffe... -
News Trump's generic drug tariffs set to reshape global pharmaceutical supply chains
The US president has announced plans to impose tariffs of up to 200% on imported generic medicines from August 2028, giving manufacturers a two-year window to establish domestic production facilities. The move threatens to upend a global supply chain t... -
News Building Safer, More Responsible Pharmaceutical Supply Chains: PSCI Global Audit Insights
The Pharmaceutical Supply Chain Initiative (PSCI) has released its seventh annual Audit Findings Analysis Report, offering unprecedented insights into supplier practices across the global pharmaceutical and healthcare industry.With a record-breaking 24...